Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Proteome Sciences ( (GB:PRM) ) has provided an update.
Proteome Sciences announced that it will release its financial results for the year ending 31 December 2024 on 10 April 2025. The company will host a live presentation on 11 April 2025, led by Executive Chairman Christopher Pearce and Chief Scientific Officer Dr. Ian Pike, to discuss the results and outlook for 2025. This presentation is accessible to all existing and potential shareholders, allowing them to submit questions in advance or during the event. This announcement is significant as it provides stakeholders with insights into the company’s performance and future plans, potentially impacting investor confidence and market positioning.
More about Proteome Sciences
Proteome Sciences plc is a specialist provider of contract proteomics services aimed at facilitating drug discovery, development, and biomarker identification. The company employs proprietary workflows for optimal analysis of tissues, cells, and body fluids, offering methods like SysQuant® and TMT®MS2 for identifying new targets and defining biological mechanisms. Their Super-Depletion and TMTcalibrator™ technologies enable access to over 8,500 circulating plasma proteins for disease-related biomarker discovery, while mass spectrometry is used for high-sensitivity biomarker analyses.
YTD Price Performance: 19.41%
Average Trading Volume: 155,558
Technical Sentiment Signal: Hold
Current Market Cap: £11.98M
See more insights into PRM stock on TipRanks’ Stock Analysis page.